Skip to main content
. 2012 Sep 18;35(5):1675–1690. doi: 10.1007/s11357-012-9470-2

Fig. 4.

Fig. 4

Striatal levels (nanogram per milligram wet weight of tissue) of dopamine (a) and its metabolite DOPAC (b) in control rats as compared with rats subjected to CHP or chronic cerebral hypoperfusion and treatment with the AT1 blocker candesartan (CHP + cand). Data are means ± SEM. *p < 0.05 relative to the control group, #p < 0.05 relative to the group subjected to chronic hypoperfusion (one-way ANOVA and Bonferroni post hoc test)